AbbVie (ABBV) closed at $285.47 on Oct 16, 2026, up 0.7% on the day. The stock is up 8.1% over the past month, up 12.7% over three months, up 27.0% year to date and up 28.3% over the past year. It trades 2.0% below its 52-week high of $291.40 and 49.5% above its 52-week low of $191.00. The close sits above its 50-day moving average ($262.45) and above its 200-day moving average ($233.07).
NextPick tracks ABBV in its Pharma basket alongside JNJ, MRK, RHHBY, NVS and AZN. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month ABBV ranks 2nd of 12 basket members by price change.
ABBV is scheduled to report earnings on Oct 30, 2026. Over its last 8 reports the stock moved an average of 3.5% on the first trading day after earnings, beating the options-implied move in 3 of 8.
ABBV options were pricing 31% at-the-money implied volatility on Oct 8, 2026, an IV rank of 67 over the past year.
AbbVie is scheduled to report on Oct 30, 2026.
Over the last 8 reports, ABBV moved an average of 3.5% on the first trading day after earnings. The move beat the options-implied move in 3 of 8 reports.
Yes — the Oct 16, 2026 close of $285.47 is 22.5% above the 200-day average of $233.07.
ABBV closed 2.0% below its 52-week high of $291.40.
NextPick groups ABBV with JNJ, MRK, RHHBY, NVS and AZN in its Pharma basket.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
